Granted Patent B2

US 12,522,648 · App. 17/484,003 · Granted Jan 13, 2026

Inventors: Tomoyuki Igawa (Shizuoka, JP); Naoka Hironiwa (Shizuoka, JP); Shojiro Kadono (Kanagawa, JP); Atsushi Matsuo (Shizuoka, JP); Taichi Kuramochi (Shizuoka, JP); Futa Mimoto (Shizuoka, JP)

Assignee: Chugai Seiyaku Kabushiki Kaisha

C07K16/00C07K16/22C07K16/2848C07K2317/52C07K2317/524C07K2317/71C07K2317/72C07K2317/732C07K2317/94C07K2319/30

Abstract

Claims (80)

1 . A method of treating a tumor in a subject, the method comprising

identifying the subject as having a tumor that expresses a first antigen, and

administering an antibody comprising an antibody variable region that binds to the first antigen and an Fc region dimer comprising a first IgG1 Fc region and a second IgG1 Fc region,

wherein the first and second IgG1 Fc regions each comprise a CH2 domain;

wherein the CH2 domain of either or both of the first and second IgG1 Fc regions comprises an antigen-binding site that binds to a second antigen different from the first antigen;

wherein the antigen-binding site is within loop 2, loop 3, or loop 4 of one of the CH2 domains;

wherein the second antigen is a molecule naturally expressed on an immunocyte or on both a tumor cell and a normal cell, and is not an FcγR;

wherein the Fc region dimer comprises an FcγR-binding site that binds to FcγRIIIa;

wherein the Fc region dimer does not bind to both the second antigen and FcγRIIIa at the same time;

wherein the antibody can treat the tumor (A) by crosslinking a tumor cell and the immunocyte, or (B) by crosslinking a tumor cell and a cell expressing FcγRIIIa, or both (A) and (B);

wherein each of the following EU numbering positions in the first IgG1 Fc region is occupied by the amino acid residue specified for that position:

position 234: Tyr,

position 236: Trp, and

position 298: Ala; and

wherein each of the following EU numbering positions in the second IgG1 Fc region is occupied by the amino acid residue specified for that position:

position 239: Asp,

position 330: Leu, and

position 332: Glu.

2 . The method of claim 1 , wherein the second antigen is a molecule naturally expressed on an immunocyte, and is not an FcγR.

3 . The method of claim 1 , wherein the second antigen is a molecule naturally expressed both on a tumor cell and on a normal cell, and is not an FcγR.

4 . The method of claim 1 , wherein the second antigen is a T cell surface molecule other than an FcγR.

5 . The method of claim 1 , wherein the amino acid sequence of the antigen-binding site of the Fc region dimer comprises at least one amino acid residue that differs from the residue present at the corresponding position in SEQ ID NO: 49.

6 . The method of claim 5 , wherein the at least one amino acid residue is at a position selected from EU numbering positions 231, 232, 233, 234, 235, 236, 237, 238, 239, 265, 266, 267, 268, 269, 270, 271, 295, 296, 297, 298, 299, 300, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, and 337.

7 . The method of claim 1 , wherein the antigen-binding site comprises three to twelve amino acid residues located within loop 2, loop 3, or loop 4 of one of the CH2 domains.

8 . The method of claim 1 , wherein the antigen-binding site comprises one or more amino acid residues inserted between two contiguous EU numbering positions in loop 2, loop 3, or loop 4 of one of the CH2 domains.

9 . The method of claim 1 , wherein the antigen-binding site comprises one to nine amino acid residues inserted between two contiguous EU numbering positions in loop 2, loop 3, or loop 4 of one of the CH2 domains.

10 . The method of claim 1 , wherein the antigen-binding site comprises three to nine amino acid residues inserted between two contiguous EU numbering positions in loop 2, loop 3, or loop 4 of one of the CH2 domains.

11 . The method of claim 1 , wherein the antigen-binding site comprises a peptide that is three to nine amino acid residues in length, wherein the amino acid sequence of the peptide is not present in the amino acid sequence of any of SEQ ID NOs: 49-52.

12 . The method of claim 11 , wherein the peptide binds the second antigen.

13 . The method of claim 1 , wherein the FcγR-binding site (i) binds to FcγRIIIa, (ii) has an amino acid sequence that differs from the sequence of the FcγR-binding site of a naturally occurring human IgG that binds to FcγRIIIa, and (iii) binds more strongly to FcγRIIIa than does the naturally occurring human IgG.

14 . The method of claim 1 , wherein the FcγR-binding site binds more strongly to FcγRIIIa than an FcγR-binding site of a homodimer of SEQ ID NO: 49 binds to FcγRIIIa.

15 . The method of claim 1 , wherein the amino acid sequence of the FcγR-binding site of the Fc region dimer comprises one or more amino acid residues that differ from the residue present at the corresponding position(s) in each of SEQ ID NOs: 49-52.

16 . The method of claim 15 , wherein at least one of the one or more amino acid residues is in the CH2 domain of the first IgG1 Fc region, or the CH2 domain of the second IgG1 Fc region, or both.

17 . The method of claim 1 , wherein the amino acid sequence of the FcγR-binding site of the Fc region dimer is identical to the FcγR-binding site of a naturally occurring human IgG1.

18 . The method of claim 1 , wherein at least one of the following EU numbering positions in the first IgG1 Fc region is occupied by an amino acid residue specified for that position:

position 235: Tyr or Gln,

position 239: Asp or Met,

position 268: Asp,

position 270: Glu,

position 326: Asp,

position 330: Leu or Met,

position 332: Glu, and

position 334: Glu.

19 . The method of claim 1 , wherein

(a) at least one of the following EU numbering positions in the first IgG1 Fc region is occupied by an amino acid residue specified for that position:

position 235: Tyr or Gln,

position 239: Met,

position 268: Asp, and

position 270: Glu,

or

(b) at least one of the following EU numbering positions in the second IgG1 Fc region is occupied by an amino acid residue specified for that position:

position 270: Glu,

position 326: Asp, and

position 334: Glu;

or

(c) both (a) and (b).

20 . The method of claim 1 , wherein the first IgG1 Fc region comprises one of the following two sets of amino acid residues at the respective specified EU numbering positions:

set (i):

Tyr at position 234,

Tyr at position 235,

Trp at position 236,

Asp at position 268, and

Ala at position 298;

set (ii):

Tyr at position 234,

Gln at position 235,

Trp at position 236,

Met at position 239,

Asp at position 268,

Glu at position 270, and

Ala at position 298.

21 . The method of claim 2 , wherein:

the second antigen is a molecule that (1) is naturally expressed on the surface of an immunocyte having cytotoxic activity, and (2) is not an FcγR; and

when the antibody binds simultaneously to both the first antigen on the tumor cell and the second antigen on the immunocyte, the antibody crosslinks the tumor cell and the immunocyte; and

when the antibody binds simultaneously to both the first antigen on the tumor cell and to FcγRIIIa on a cell that expresses FcγRIIIa, the antibody crosslinks the tumor cell and the cell that expresses FcγRIIIa; and

because the antibody does not bind to the second antigen and FcγRIIIa at the same time, the antibody does not crosslink the immunocyte and the cell that expresses FcγRIIIa.

22 . The method of claim 1 , wherein the amino acid sequences of the first and second IgG1 Fc regions differ from each other at one or more positions, including at least one position selected from EU numbering positions 265, 266, 267, 268, 269, 270, 271, 295, 296, 297, 298, 299, 300, 324, 325, 326, 327, 328, 329, 330, 331, and 332.

23 . The method of claim 1 , wherein at least one difference between the first and second IgG1 Fc regions is at a position selected from EU numbering positions 234, 235, 236, 239, 268, 270, 298, 326, 330, 332, and 334.

24 . The method of claim 2 , wherein the second antigen is selected from CD3, TCR, NKG2D, CD137, OX40, GITR, CD40, TLR1 to TLR10 and C type lectin.

25 . The method of claim 3 , wherein the second antigen is selected from integrin, tissue factor, VEGFR, PDGFR, EGFR, IGFR, MET chemokine receptor, heparan sulfate proteoglycan, CD44, fibronectin, DR5, and TNFRSF.

Assignments (1)

Priority Claims (1)

Continuity (2)

References Cited (400)